Research has raised concerns about a possible association between Depo-Provera and certain brain tumors. This article summarizes the science and what it means for women who used the injection and later developed a meningioma.
Recent scientific research has identified a potential connection between Depo-Provera, an injectable contraceptive medication, and the development of brain tumors known as meningiomas. This connection has raised important questions for women who have used the medication, particularly those who used it for extended periods.
Understanding the relationship between Depo-Provera and brain tumors can help you make informed decisions about your health and legal options. This article explores what current research shows about this potential link and what it may mean for women who have used the medication.
Understanding the Depo-Provera and Brain Tumor Connection
Depo-Provera contains the hormone medroxyprogesterone acetate, which is a type of progestogen. Scientific research has identified a potential link between progestogen-containing medications like Depo-Provera and the development of meningiomas, which are tumors that form in the protective membranes surrounding the brain and spinal cord.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Studies have found that women who used progestogen-based contraceptives, including Depo-Provera, for extended periods may have an increased risk of developing meningiomas. The risk appears to be higher in women who used the medication for longer durations, suggesting a dose-response relationship. This means that the longer someone used Depo-Provera, the greater their potential risk.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The mechanism by which progestogens may contribute to meningioma development is not fully understood, but research suggests that these hormones may stimulate the growth of meningioma cells. Meningiomas have been found to have receptors for progestogen hormones, which may explain why exposure to these hormones could promote tumor growth.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationWhat Are Meningiomas?
Meningiomas are brain tumors that form in the meninges, the protective membranes that surround the brain and spinal cord. While most meningiomas are benign, meaning they are not cancerous, they can still cause serious problems. These tumors can grow large enough to press against the brain, causing symptoms such as headaches, vision problems, seizures, and cognitive changes.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Meningiomas are typically diagnosed through imaging studies such as MRI or CT scans. In some cases, a biopsy may be performed to confirm the diagnosis. Treatment options vary depending on the size and location of the tumor, and may include monitoring, surgery, or radiation therapy.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
The connection between meningiomas and hormone exposure has been the subject of scientific research for many years. Studies have found that meningiomas have receptors for certain hormones, including progestogens, which may explain why exposure to these hormones could promote tumor growth.
Research on Depo-Provera and Brain Tumors
Scientific research examining the connection between Depo-Provera and brain tumors has been ongoing. Several studies have investigated whether women who used progestogen-containing contraceptives have an increased risk of developing meningiomas.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Some research has found that women who used progestogen-based contraceptives for extended periods may have an increased risk of developing meningiomas. The risk appears to be higher in women who used the medication for longer durations, suggesting that cumulative exposure may be a factor.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
However, it's important to note that research in this area continues to evolve. Not all studies have found the same results, and the scientific community continues to investigate this potential connection. The relationship between hormone exposure and meningioma development is complex and may involve multiple factors.
Risk Factors for Brain Tumors
While research suggests a potential link between Depo-Provera and meningiomas, it's important to understand that multiple factors may influence brain tumor development. These factors can include:
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewDuration of Medication Use: Women who used Depo-Provera for extended periods, particularly five years or more, may have a higher risk. The cumulative exposure from repeated injections over many years may be a factor.
Age: Age may be a factor in meningioma development, with some research suggesting that older women may have different risk profiles.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Genetic Factors: Some individuals may have genetic factors that influence their risk of developing meningiomas.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Other Hormone Exposure: Exposure to other hormones, including estrogen, may also play a role in meningioma development.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Individual Health Factors: Other health conditions and factors may influence an individual's risk.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityIt's important to discuss your individual risk factors with your healthcare provider, who can help you understand your specific situation and recommend appropriate monitoring or screening.
Symptoms of Brain Tumors
Meningiomas can cause a variety of symptoms depending on their size and location. Understanding these symptoms can help you recognize potential warning signs and seek appropriate medical care.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Headaches: Persistent or worsening headaches are one of the most common symptoms of meningiomas. These headaches may be different from typical headaches and may worsen over time.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationVision Problems: Meningiomas located near the optic nerve or other visual pathways can cause vision changes, including blurred vision, double vision, or loss of vision in one or both eyes.
Seizures: Some meningiomas can cause seizures, particularly if they're located in areas of the brain that control motor function or consciousness.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Cognitive Changes: Meningiomas may cause changes in memory, concentration, or other cognitive functions, especially if they're large or located in areas that affect brain function.
Weakness or Numbness: Depending on the location of the tumor, meningiomas can cause weakness or numbness in various parts of the body.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Hearing Loss: Meningiomas located near the auditory nerve can cause hearing loss or ringing in the ears.
It's important to note that these symptoms can have many causes, and having these symptoms doesn't necessarily mean you have a meningioma. However, if you've used Depo-Provera and are experiencing any of these symptoms, it's important to discuss them with your healthcare provider and consider whether imaging studies may be appropriate.
What to Do If You're Concerned
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitIf you've used Depo-Provera and are concerned about your risk of developing a brain tumor, there are several steps you can take:
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Talk to Your Healthcare Provider: Discuss your concerns with your healthcare provider, who can help you understand your individual risk factors and recommend appropriate monitoring or screening.
Know the Symptoms: Be aware of the symptoms of meningiomas and seek medical attention if you experience any concerning symptoms.
Consider Your Legal Options: If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, you may want to learn about your legal options. A free case review can help determine whether you may qualify for a lawsuit.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Stay Informed: Research in this area continues to evolve. Stay informed about new developments and discuss them with your healthcare provider.
Legal Considerations
If you've used Depo-Provera and been diagnosed with a meningioma, you may have legal options. Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers. If you've used Depo-Provera for an extended period and developed a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A free case review can help you understand your potential rights and options. This initial evaluation is confidential and does not create any obligation on your part. If you're ready to begin, you can contact us for a free case review.
Important Considerations
Understanding the connection between Depo-Provera and brain tumors requires recognizing several important points:
Research Continues to Evolve: Scientific research in this area continues to develop, and new findings may emerge that change our understanding of this connection.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Individual Risk Varies: Individual risk factors vary, and not everyone who uses Depo-Provera will develop a meningioma.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Multiple Factors May Be Involved: The relationship between hormone exposure and meningioma development is complex and may involve multiple factors beyond medication use.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Medical Monitoring May Be Appropriate: If you've used Depo-Provera for extended periods, your healthcare provider may recommend appropriate monitoring or screening.
Legal Options May Be Available: If you've been diagnosed with a meningioma after using Depo-Provera, you may have legal options. A free case review can help determine whether you may qualify.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Frequently Asked Questions
- Q: What is the connection between Depo-Provera and brain tumors?
- A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitResearch has identified a potential link between progestogen-containing medications like Depo-Provera and the development of meningiomas, which are brain tumors that form in the protective membranes surrounding the brain and spinal cord.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
- Q: How common are brain tumors in Depo-Provera users?
- The exact risk is not fully understood, but research suggests that women who used Depo-Provera for extended periods may have an increased risk of developing meningiomas.
- Q: What should I do if I've used Depo-Provera and am concerned about brain tumors?
- If you're concerned, discuss your concerns with your healthcare provider, who can help you understand your individual risk factors and recommend appropriate monitoring or screening.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
- Q: What are the symptoms of meningiomas?
- Symptoms can include headaches, vision problems, seizures, cognitive changes, weakness or numbness, and hearing loss, depending on the size and location of the tumor.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
- Q: Can I still develop a brain tumor if I stopped using Depo-Provera years ago?
- According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The timing between medication use and tumor development is complex, and tumors may develop years after medication use. If you're concerned, discuss your situation with your healthcare provider.
- Q: What legal options do I have if I've been diagnosed with a meningioma after using Depo-Provera?
- A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you've used Depo-Provera and been diagnosed with a meningioma, you may have legal options. A free case review can help determine whether you may qualify for a lawsuit.
- Q: How long do I have to file a lawsuit?
- Statutes of limitations vary by state and depend on factors such as when you discovered your injury and when you were diagnosed. It's important to act promptly if you believe you may have a claim.
Important Disclaimers
Understanding the connection between Depo-Provera and brain tumors is important for women who have used the medication. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is important.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Medical liens and health-plan reimbursement can reduce net recovery. Experienced firms negotiate those items as part of settlement strategy when applicable.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
